Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC4908 SS-thujaplicinol Inhibitor of the replication of herpes simplex viruses 1 and 2 (HSV-1 and HSV-2)
DCC4909 Sstr3-agonist-5c Novel non-peptidic highly potent somatostatin receptor 3 (SSTR3) agonist
DCC4910 Sstr3-antagonist-3a Novel potent sstr3 antagonist, showing to reduce glucose excursion in a mouse oGTT assay
DCC4911 Sstr5a Novel somatostatin receptor subtype 5 antagonist, stimulating glucoseinduced GLP-1 secretion, reducing blood glucose in a gut- and GLP-1R-dependent manner
DCC4912 St026567 Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs
DCC4913 St029248 Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs
DCC4914 St056083 Novel inhibitor of the c-di-AMP synthetase DNA integrity scanning protein (DisA) in vitro
DCC4915 St101036 Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs
DCC4916 st-1032 Novel histamine H3 receptor ligand
DCC4917 St1237 Potent, direct, non-cytotoxic Arachidonate_5-lipoxygenase>5-lipoxygenase (5-LO) inhibitor
DCC4918 St-161 Antiviral agent against LASV and a number of other viruses in the Arenaviridae family
DCC4919 St-1703 Novel histamine H3 receptor ligand
DCC4920 St-1892 Novel highly potent and soluble partial FXR agonist
DCC4921 St-198 Seletive dopamine D3 receptors
DCC4922 St-1992 Novel potent A 1 R/A 2A R/H 3 R multitargeting ligand (MTL)
DCC4923 St-2001 Novel potent A 1 R/A 2A R/H 3 R multitargeting ligand (MTL)
DCC4924 St-2262 Novel selective NaV1.7 inhibitor, blocking the extracellular vestibule of the channel with an IC50 of 72 nM and greater than 200-fold selectivity over off-target sodium channel isoforms, NaV1.1-1.6 and NaV1.8
DCC4925 St4070 Highly selective FAAH>fatty acid amide hydrolase (FAAH) inhibitor
DCC4926 St7710aa1 Novel PARP-1 inhibitor, showing significant in vitro target inhibition and capability to substantially bypass the multidrug resistance mediated by Pgp
DCC4927 Sta-9584 Novel tubulin-binding vascular disrupting agent (VDA)
DCC4928 Stad-2 Cell permeable AKAP disruptor, selectively binding to PKA-RII and blocking the interaction of PKA-RI with AKAP
DCC4929 Stalobacin I Novel Lipopeptide Antibiotic with Potent Antibacterial Activity against Multidrug-Resistant Bacteria
DCC4930 Stanozolol [10418-03-8] Anabolic-androgenic steroid (AAS), acting as an agonist of the androgen receptor (AR)
DCC4931 Stat3 -in-11 Novel STAT3 inhibitor, selectively inhibiting STAT3 phosphorylation and exhibiting potent antitumor activity
DCC4932 stat3 Inhibitor 6 Novel inhibitor of STAT3 signaling pathway
DCC4933 Stat3-in-13r Novel inhibitor of STAT3, targeting SH2 domain
DCC4934 Stat3-in-3 Novel potent and selective inhibitor of STAT3
DCC4935 Stat3-in-a69 Novel inhibitor targeting the DNA-binding domain of STAT3, suppressing tumor growth, metastasis and STAT3 target gene expression in vivo
DCC4936 Stat3-in-b9 Novel inhibitor of signal transducer and activator of transcription 3 (STAT3), inhibiting the proliferation of tumor cells harboring abnormal activation of STAT3, such as, MDA-MB-468, MDA-MB-231 and DU145
DCC4937 Stat5a-in-27 Novel cell-permeable selective STAT5a inhibitor prodrug, inhibiting tyrosine phosphorylation of STAT5a with selectivity over STAT5b in cultured human leukemia cells, and representing a valuable tool to define the non-redundant molecular functions of the t

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X